Literature DB >> 7379049

Phase II study of VM-26 in adult malignancies.

E Spremulli, J J Schulz, V J Speckhart, G L Wampler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7379049

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  10 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Phase II study of teniposide in advanced breast cancer.

Authors:  J Boas; D Rasmussen; O P Hansen; S A Engelholm; P Dombernowsky
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 4.  VM26: phase I and II studies.

Authors:  F R Macbeth
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  VM-26 in colorectal carcinoma: a Southwest Oncology Group study.

Authors:  N Oishi; T R Fleming; L Laufman; J S Ungerleider; R B Natale; A B Einstein; D D Von Hoff; J S Macdonald
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

7.  Early chemotherapy and concurrent radio-chemotherapy in high grade glioma.

Authors:  A A Brandes; A Rigon; P Zampieri; E Scelzi; P Amistà; F Berti; A Rotilio; M Gardiman; M V Fiorentino
Journal:  J Neurooncol       Date:  1996-12       Impact factor: 4.130

Review 8.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.

Authors:  P Canal; R Bugat; C Michel; H Roche; G Soula; P F Combes
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.

Authors:  E B Cox; C L Vogel; J T Carpenter; M Raney
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.